Perinatal risk when planning pregnancy in women with severe cardiac pathology

Authors

  • Т. Ф Татарчук Institute of Pediatrics, Obstetrics and Gynecology, NAMS of Ukraine, Ukraine
  • Ю. В. Давыдова Institute of Pediatrics, Obstetrics and Gynecology, NAMS of Ukraine, Ukraine

DOI:

https://doi.org/10.18370/2309-4117.2014.19.42-46

Keywords:

women with cardiac pathology, perinatal risk, contraception

Abstract

Quality counseling and the use of modern contraceptives in women with cardiac pathology allow reducing maternal and perinatal mortality, gynecological morbidity and preventing complications associated with unwanted pregnancy.

Levonorgestrel-releasing intrauterine systems have minimal systemic eff ects and no adverse eff ects on carbohydrate and lipid metabolism, which is important for women with cardiac pathology and makes use of the levonorgestrel-releasing intrauterine systems a method of choice in these patients

Author Biographies

Т. Ф Татарчук, Institute of Pediatrics, Obstetrics and Gynecology, NAMS of Ukraine

MD, professor, corresponding member. NAMS of Ukraine, Deputy Director for Research, Head of Endocrine Gynecology

Ю. В. Давыдова, Institute of Pediatrics, Obstetrics and Gynecology, NAMS of Ukraine

MD, Head of the Obstetrical Problems of Extragenital Pathology Department

References

  1. Butchart E.G., Gohlke-Barwolf C., Antunes M.J., Tornos P, De Caterina R. et al. «Recommendations for the management of patients after heart valve surgery.» Eur Heart J, 26(2005):2463-2471.
  2. Child J.S. «Management of Pregnancy and contraception in Congenital Heart Disease.» In: Congenital Heart Disease in Adults, 3rd ed, Perloff J.K., Child J.S., Aboulhosn J. (Eds), Saunders/Elsevier (2009).
  3. European Society of Gynecology (ESG), Association for European Paediatric Cardiology (AEPC), German Society for Gender Medicine (DGesGM) et al. «ESC Guidelines on the management of cardiovascular diseases during pregnancy: the Task Force on the Management of Cardiovascular Diseases during Pregnancy of the European Society of Cardiology (ESC).» Eur Heart J, 32(2011):3147.
  4. Kovacs A.H., Harrison J.L., Colman J.M. et al. «Pregnancy and contraception in congenital heart disease: what women are not told.» J Am Coll Cardiol, 52(2008):577-578.
  5. Miner P. «Contraceptive choices for females with congenital heart disease.» Prog Pediatr Cardiol, 19(2004):15-24.
  6. Thorne S., Mac Gregor A., Nelson-Piercy C. «Risks of contraception and pregnancy in heart disease.» Heart, 92(2006): 1520-1525.
  7. Task force on the Management of Cardiovascular Diseases during «Pregnancy of the European Society of Cardiology Expert consensus document on management of cardiovascular diseases during pregnancy.» Eur Heart J, 24(2003):761-781.
  8. Winkler U.H., Howie H., Buehler K. et al. «A randomized controlled double-blind study of the eff ects on hemostasis of two progestogen-only pills containing 75 mcg desogestrel and 30 mcg levonorgestrel.» Contraception, 57(1998): 385-92.
  9. Barkfeldt J., Virkkunen A., Dieben T. «The eff ects of two progestogen-only pills containing either desogestrel (75 mcg/ day) or levonorgestrel (30 mcg/day) on lipid metabolism.» Contraception, 64(5) (2001): 295-300.
  10. Kivelae A., Ruuskanen M., Aegren U., Dieben T. «The eff ects of two progestogen-only pills containing either desogestrel (75 mcg/ day) or levonorgestrel (30 mcg/day) on carbohydrate metabolism nd adrenal and thyroid function.» Eur J Contracept Reprod Health Care, 6(2001): 71-7.
  11. Инструкция по медицинскому применению препарата Лактинет.
  12. WHO «Medical eligibility criteria for contraceptive use.» 4th edition. Geneva (2009).

Published

2014-10-20

How to Cite

Татарчук, Т. Ф., & Давыдова, Ю. В. (2014). Perinatal risk when planning pregnancy in women with severe cardiac pathology. REPRODUCTIVE ENDOCRINOLOGY, (19), 42–46. https://doi.org/10.18370/2309-4117.2014.19.42-46

Issue

Section

Contraception

Most read articles by the same author(s)

1 2 3 4 5 6 7 8 9 > >>